Pfizer Inc PFE

$29.25 +0.02 (0.07%)

Valuation

Market cap
167,518,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.80
P/E (forward)
9.87
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
15,682,679
Avg volume
33,988,637
Day's range
$28.95 – $29.29
Shares out
5,699,854,000
Stochastic %K
24%
Beta
0.31
Analysts
Hold
Price target
$30.35

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Stocktradesmoon Nov 10, 6:59 PM
$ABCL $IAM $REGN $PFE $HIMS $ABCL is down today but very low volume. It can flip green in a hurry.
0 replies
Comicguy Nov 10, 6:53 PM
$PFE Curling
0 replies
taxplanr Nov 10, 6:37 PM
Trust the political science $MRNA $PFE $BX Epstein
1 replies
Stocktradesmoon Nov 10, 6:34 PM
$ABCL $HIMS $IBRX $MRNA $PFE ABcellera 🔥 🔥!!! 😉👀🚀👑
0 replies
TraderDaKing Nov 10, 6:12 PM
$ELTP $GME $JNJ $PFE In late 2025, Elite Pharmaceuticals’ management explicitly stated that pursuing mergers and acquisitions (M&A) was a preferred strategic path. The company set a soft deadline through the end of 2025 into early 2026 to see if an attractive M&A or buyout deal materialized. If no suitable deal emerged, management planned to shift focus toward uplisting the stock from the OTC market to the NASDAQ exchange. • Asset Appeal: Elite holds strong market positions in key generic lines, particularly central nervous system (CNS) medications like ADHD drugs • Infrastructure: Its physical facility space is set up to handle controlled substances, which is an attractive operational footprint for larger pharmaceutical buyers. • Elite added new board members, including John W. LaRocca, Esq., and Aqeel A. Fatmi, Ph.D.. Retail investors have speculated that bringing on individuals with legal, regulatory, and pharma integration experience could be a sign.
0 replies
Stocktradesmoon Nov 10, 5:43 PM 0 replies
BuyHi Nov 10, 5:37 PM
$PFE gamma
0 replies
BarkingPuppy Nov 10, 5:26 PM
$META $ELTP $PFE $GME ELTP is in play.... News 2027 ( around May )
0 replies